CurrentBlue Cross Blue Shield - OklahomaPolicy CPCPLAB019

Thyroid Disease Testing laboratory reimbursement criteria

Defines Blue Cross Blue Shield of Oklahoma laboratory reimbursement criteria for thyroid function and related antibody testing, applicable to plan-specific coverage (not all requirements apply to every product). Includes covered and non-reimbursable tests, monitoring intervals, and procedure code guidance.

Policy Summary

PayerBlue Cross Blue Shield - Oklahoma

PolicyThyroid Disease Testing laboratory reimbursement criteria

Policy CodePolicy CPCPLAB019

Change TypeRevised (includes code addition)

Effective DateJan 15, 2025

Next Review Date

Key ActionProviders must submit accurate documentation of clinical signs/symptoms, treatment changes, or high-risk indications to support thyroid testing reimbursement.

SourceLink

POLICY UPDATE CHANGES

Document updated with literature review and reimbursement information edits; effective date 01/15/2025.

Added code 83520 to procedure code list.

16Procedure codes listed

SeveralReimbursable clinical indications

5Explicit not-reimbursable test categories

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Policy Summary & Scope

BCBSOK has implemented laboratory reimbursement criteria for thyroid function testing that define when TSH, free T4, free/total T3, antibody testing, and related assays may be reimbursable; these criteria include indications, monitoring intervals, and tests that are not reimbursable. Not all requirements apply to every product, and providers should consult plan-specific documents and submit accurate clinical documentation and appropriate coding to support reimbursement.

Policy metadata and thresholds

policy_numberCPCPLAB019

subjectThyroid Disease Testing laboratory reimbursement criteria

effective_date2025-01-15

last_review2024-10-30

next_review

coverage_stancemixed

Pregnancy/postpartum thyroid testing frequencyTSH and fT4 once every 4 weeks when symptomatic

Monitoring after hyperthyroidism treatmentRepeat testing of TSH and fT4 every 8 weeks during treatment; annual thereafter

Monitoring after hypothyroidism treatment (primary)TSH and fT4 every 6 weeks upon dosage change; annually if stable

Monitoring after hypothyroidism treatment (secondary)fT4 every 6 weeks upon dosage change; annually if stable

Immune reconstitution therapy monitoringTSH once every 3 months with reflex fT4 and fT3 when TSH abnormal

Reimbursable Thyroid Function Testing Criteria

Reimbursable Thyroid Function Testing

Thyroid function testing may be reimbursable when the following clinical criteria or monitoring indications are met:

ANY of the following

a. Individuals with signs and symptoms consistent with hypothyroidism
- TSH testing to confirm or rule out primary hypothyroidism
- Free T4 (fT4) testing as a follow up to abnormal TSH findings
- TSH and fT4 testing in cases of suspected secondary hypothyroidism
- Monitoring for individuals being treated for primary hypothyroidism

Not Reimbursable Tests and Limitations

Not Reimbursable Tests / Limitations

Tests and uses that are not reimbursable per policy:

ALL of the following

TRH or TBG testing to evaluate cause of hyperthyroidism or hypothyroidism is not reimbursable
Testing of reverse T3, T3 uptake, and total T4 for all other situations not mentioned above is not reimbursable
Measurement of total T3 (TT3) and/or free T3 (fT3) to assess hypothyroidism is not reimbursable
Measurement of total or free T3 to assess levothyroxine dose in hypothyroid individuals is not reimbursable

Procedure Codes & Coding Guidance

Procedure Codes (listed in policy - inclusion does not guarantee coverage)mixed

80438
80439
83519
83520
84432
84436
84439
84442
84443
84445

1–10 of 16

1/2

Billing Rule

Code use guidance

Claims should be coded using valid HIPAA‑approved code sets and industry coding guidelines. Inclusion of a procedure code in the policy’s code list does not guarantee coverage or reimbursement.

80438
80439
83519
83520
84432
84436
84439
84442
84443
84445
84479
84480
84481
84482

Documentation, Billing & Claims Risks

Documentation Required

Clinical indication documentation required

Providers must submit accurate documentation of clinical signs/symptoms, treatment changes, or high‑risk indications to support reimbursement for thyroid testing.

Clinical signs/symptoms consistent with hypothyroidism or hyperthyroidism (see policy Note 1 and Note 2)
Documentation of treatment changes and monitoring intervals (e.g., dosage changes requiring testing every 6–8 weeks as specified)
Evidence of high‑risk status or indication for one‑time screening (personal/family history, autoimmune disease, thyroid or endocrine neoplasm, chronic/acute urticaria, short stature, failure‑to‑thrive)

Denial Risk

Claims subject to claim review and code edits

Claims are subject to code edit protocols and medical policy review; if submitted documentation does not support the medical necessity of the test, the claim may be denied.

Key Terms

Definitions

TSHThyroid stimulating hormone

fT4Free thyroxine (free T4)

TT3 / fT3Total or free triiodothyronine (T3)

IRTImmune reconstitution therapy (examples: alemtuzumab, HAART, BMT/HSCT contexts)

Background & Evidence

This document was updated with a literature review and reimbursement information edits on 10/30/2024 (policy effective date 01/15/2025); changes included reorganizing and clarifying thyroid function testing subcriteria, adding fT4 monitoring for secondary hypothyroidism, consolidating one-time TSH screening reasons, adding TSH with reflex fT4/fT3 for immune reconstitution therapy, specifying monitoring frequencies, and adding CPT/HCPCS code 83520. Not all requirements apply to every product — providers should review product-specific plan documents.

Policy Changes & Effective Dates

2025-01-15revisedLatest

Document updated with literature review and reimbursement information edits; effective date 01/15/2025.

2024-10-30reviewed

Policy approved on October 30, 2024; literature review conducted and references updated.

revised

Policy Summary

PayerBlue Cross Blue Shield - Oklahoma

PolicyThyroid Disease Testing laboratory reimbursement criteria

Policy CodePolicy CPCPLAB019

Change TypeRevised (includes code addition)

Effective DateJan 15, 2025

Next Review Date

Key ActionProviders must submit accurate documentation of clinical signs/symptoms, treatment changes, or high-risk indications to support thyroid testing reimbursement.

SourceLink

On This Page

TSH and fT4 every 6 weeks upon dosage change; annually in stable individuals

Monitoring for individuals being treated for secondary hypothyroidismfT4 testing every 6 weeks upon dosage change; annually in stable individuals

b. Individuals with signs and symptoms consistent with hyperthyroidism

TSH testing to confirm or rule out overt hyperthyroidism
Free T4 testing as a follow up to abnormal TSH findings
Total T3 (TT3) or free T3 (fT3) testing to confirm a diagnosis of hyperthyroidism
Free T4 testing to distinguish between overt and subclinical hyperthyroidism
Monitoring after treatment for hyperthyroidismRepeat testing of TSH and fT4 every 8 weeks during treatment; annual monitoring after first year

c. Asymptomatic individuals prescribed drugs that can interfere with thyroid function

Annually
When dosage or medication changes
If symptoms consistent with thyroid dysfunction develop

d. Individuals capable of becoming pregnant

TSH testing for those undergoing evaluation for infertility
TSH testing for those who have experienced two or more pregnancy losses

e. One-time TSH screening for asymptomatic high-risk individuals

Personal or family history of thyroid dysfunction
Personal or family history of type 1 diabetes or other autoimmune disease
Individuals with disease or neoplasm of the thyroid or other endocrine glands
Individuals with chronic or acute urticaria
Pediatric individuals diagnosed with short stature
Pediatric individuals with a clinical finding of failure-to-thrive

f. Individuals undergoing immune reconstitution therapy (IRT)

TSH testing once every 3 months with reflex fT4 and fT3 when TSH is abnormal
Includes: individuals with active relapsing remitting MS undergoing alemtuzumab; individuals with HIV undergoing HAART; individuals following allogeneic BMT or HSCT

g. Individuals with hypothalamic-pituitary disease (monitoring)

For individuals <18 years: monitor TSH and fT4 biannually
For individuals ≥18 years: monitor TSH and fT4 annually

h. Primary mitochondrial disease

Annual screening of TSH and fT4

Pregnancy and postpartum with symptoms

TSH and fT4 testing once every 4 weeks may be reimbursable
See Note 3 re: trimester-specific reference ranges and preferred assays

Pregnancy/postpartum diagnosed hyperthyroidism

TT4, Tg-Ab, TRAb, and TPOAb testing may be reimbursable
See Note 3 re: trimester-specific reference ranges and preferred assays

Thyroid cancer surveillance

Testing for serum thyroglobulin and/or Tg-Ab levels for detection of tumor recurrence, post-surgical evaluation, surveillance, and maintenance for differentiated thyroid carcinomas may be reimbursable

Thyroid antibody testing for thyroid dysfunction

Testing for thyroid antibodies for individuals with hypothyroidism or hyperthyroidism may be reimbursable once every three years

Monitoring frequency thresholds

Pregnancy/postpartum thyroid testing frequencyTSH and fT4 once every 4 weeks when symptomatic

Monitoring after hyperthyroidism treatmentRepeat TSH and fT4 every 8 weeks during treatment; annual monitoring after first year

Monitoring after hypothyroidism treatment (primary)TSH and fT4 every 6 weeks upon dosage change; annually if stable

Monitoring after hypothyroidism treatment (secondary)fT4 every 6 weeks upon dosage change; annually if stable

Immune reconstitution therapy monitoring frequencyTSH once every 3 months with reflex fT4 and fT3 when TSH abnormal

Hypothalamic-pituitary disease monitoring (age <18)TSH and fT4 biannually

Hypothalamic-pituitary disease monitoring (age ≥18)TSH and fT4 annually

Testing for thyroid dysfunction during a general exam in asymptomatic nonpregnant individuals without abnormal findings is not reimbursable

Potential denial risk if documentation does not support medical necessity; providers may be asked to supply additional records and should consult plan‑specific documents and provider contracts for coverage determinations.

Added code 83520 to procedure code list.